|
1. Burke AP, Gatto-Weis C, Griego JE, Ellington KS, Virmani R. Adult cellular
rhabdomyoma of the heart: a report of 3 cases. Hum Pathol. 2002;33:1092-7.
2. Burke AP, Fonseca V, Kolodgie F, Zieske A, Fink L, Virmani R. Increased serum
homocysteine and sudden death resulting from coronary atherosclerosis with
fibrous plaques. Arterioscler Thromb Vasc Biol. 2002;22:1936-41.
3. Burke AP, Virmani R, Galis Z, Haudenschild CC, Muller JE. 34th Bethesda
Conference: Task force #2--What is the pathologic basis for new atherosclerosis
imaging techniques? J Am Coll Cardiol. 2003;41:1874-86.
4. Burke AP, Kolodgie FD, Zieske A, Fowler DR, Weber DK, Varghese PJ, Farb A,
Virmani R. Morphologic findings of coronary atherosclerotic plaques in diabetics:
a postmortem study. Arterioscler Thromb Vasc Biol. 2004;24:1266-71.
5. Burke AP, Jarvelainen H, Kolodgie FD, Goel A, Wight TN, Virmani R.
Superficial pseudoaneurysms: clinicopathologic aspects and involvement of
extracellular matrix proteoglycans. Mod Pathol. 2004;17:482-8.
6. Eckart RE, Scoville SL, Campbell CL, Shry EA, Stajduhar KC, Potter RN, Pearse
LA, Virmani R. Sudden death in young adults: a 25-year review of autopsies in
military recruits. Ann Intern Med. 2004;141:829-34.
7. Farb A, John M, Acampado E, Kolodgie FD, Prescott MF, Virmani R. Oral
everolimus inhibits in-stent neointimal growth. Circulation. 2002;106:2379-84.
8. Farb A, Burke AP, Kolodgie FD, Virmani R. Pathological mechanisms of fatal
late coronary stent thrombosis in humans. Circulation. 2003;108:1701-6.
9. Farb A, Kolodgie FD, Hwang JY, Burke AP, Tefera K, Weber DK, Wight TN,
Virmani R. Extracellular matrix changes in stented human coronary arteries.
Circulation. 2004;110:940-7.
10. Fischer JW, Steitz SA, Johnson PY, Burke A, Kolodgie F, Virmani R, Giachelli
C, Wight TN. Decorin promotes aortic smooth muscle cell calcification and
colocalizes to calcified regions in human atherosclerotic lesions. Arterioscler
Thromb Vasc Biol. 2004;24:2391-6.
11. Guagliumi G, Farb A, Musumeci G, Valsecchi O, Tespili M, Motta T, Virmani R.
Images in cardiovascular medicine. Sirolimus-eluting stent implanted in human
coronary artery for 16 months: pathological findings. Circulation. 2003;107:1340-1.
12. Kolodgie FD, Burke AP, Farb A, Weber DK, Kutys R, Wight TN, Virmani R.
Differential accumulation of proteoglycans and hyaluronan in culprit lesions:
insights into plaque erosion. Arterioscler Thromb Vasc Biol. 2002;22:1642-8.
13. Kolodgie FD, John M, Khurana C, Farb A, Wilson PS, Acampado E, Desai N,
Soon-Shiong P, Virmani R. Sustained reduction of in-stent neointimal growth
with the use of a novel systemic nanoparticle paclitaxel. Circulation.
2002;106:1195-8.
14. Kolodgie FD, Petrov A, Virmani R, Narula N, Verjans JW, Weber DK, Hartung
D, Steinmetz N, Vanderheyden JL, Vannan MA, Gold HK, Reutelingsperger CP,
Hofstra L, Narula J. Targeting of apoptotic macrophages and experimental
atheroma with radiolabeled annexin V: a technique with potential for noninvasive
imaging of vulnerable plaque. Circulation. 2003;108:3134-9.
15. Kolodgie FD, Gold HK, Burke AP, Fowler DR, Kruth HS, Weber DK, Farb A,
Guerrero LJ, Hayase M, Kutys R, Narula J, Finn AV, Virmani R. Intraplaque
hemorrhage and progression of coronary atheroma. N Engl J Med.
2003;349:2316-25.
16. Kolodgie FD, Virmani R, Burke AP, Farb A, Weber DK, Kutys R, Finn AV, Gold
HK. Pathologic assessment of the vulnerable human coronary plaque. Heart.
2004;90:1385-91.
17. Kolodgie FD, Burke AP, Wight TN, Virmani R. The accumulation of specific
types of proteoglycans in eroded plaques: a role in coronary thrombosis in the
absence of rupture. Curr Opin Lipidol. 2004;15:575-82.
18. Rubenstein MH, Finn AV, Leinbach RC, Hollenbach S, Aretz HT, Virmani R,
Gold HK. Short-term intravenous eptifibatide infusion combined with reduced
dose recombinant tissue plasminogen activator inhibits platelet recruitment at
sites of coronary artery injury. J Am Coll Cardiol. 2004;43:287-94.
19. Schaar JA, Muller JE, Falk E, Virmani R, Fuster V, Serruys PW, Colombo A,
Stefanadis C, Ward Casscells S, Moreno PR, Maseri A, van der Steen AF.
Terminology for high-risk and vulnerable coronary artery plaques. Report of a
meeting on the vulnerable plaque, June 17 and 18, 2003, Santorini, Greece. Eur
Heart J. 2004;25:1077-82.
20. Schwartz RS, Edelman ER, Carter A, Chronos N, Rogers C, Robinson KA,
Waksman R, Weinberger J, Wilensky RL, Jensen DN, Zuckerman BD, Virmani
R. Drug-eluting stents in preclinical studies: recommended evaluation from a
consensus group. Circulation. 2002;106:1867-73.
21. Schwartz RS, Edelman ER, Carter A, Chronos NA, Rogers C, Robinson KA,
Waksman R, Machan L, Weinberger J, Wilensky RL, Goode JL, Hottenstein OD,
Zuckerman BD, Virmani R. Preclinical evaluation of drug-eluting stents for
peripheral applications: recommendations from an expert consensus group.
Circulation. 2004;110:2498-505.
22. Schwartz RS, Chronos NA, Virmani R. Preclinical restenosis models and drug-
eluting stents: still important, still much to learn. J Am Coll Cardiol.
2004;44:1373-85.
23. Serruys PW, Ormiston JA, Sianos G, Sousa JE, Grube E, den Heijer P, de Feyter
P, Buszman P, Schomig A, Marco J, Polonski L, Thuesen L, Zeiher AM, Bett JH,
Suttorp MJ, Glogar HD, Pitney M, Wilkins GT, Whitbourn R, Veldhof S, Miquel
K, Johnson R, Coleman L, Virmani R. Actinomycin-eluting stent for coronary
revascularization: a randomized feasibility and safety study: the ACTION trial.
JAm Coll Cardiol. 2004;44:1363-7.
24. Sousa JE, Costa MA, Farb A, Abizaid A, Sousa A, Seixas AC, da Silva LM, Feres
F, Pinto I, Mattos LA, Virmani R. Images in cardiovascular medicine. Vascular
healing 4 years after the implantation of sirolimus-eluting stent in humans: a
histopathological examination. Circulation. 2004;110:e5-6.
25. Virmani R, Burke AP, Kolodgie FD, Farb A. Vulnerable plaque: the pathology of
unstable coronary lesions. J Interv Cardiol. 2002;15:439-46.
26. Virmani R, Liistro F, Stankovic G, Di Mario C, Montorfano M, Farb A, Kolodgie
FD, Colombo A. Mechanism of late in-stent restenosis after implantation of a
paclitaxel derivate-eluting polymer stent system in humans. Circulation.2002;106:2649-51.
27. Virmani R, Burke AP, Kolodgie FD, Farb A. Pathology of the thin-cap
fibroatheroma: a type of vulnerable plaque. J Interv Cardiol. 2003;16:267-72.
28. Virmani R, Kolodgie FD, Farb A, Lafont A. Drug eluting stents: are human and
animal studies comparable? Heart. 2003;89:133-8.
29. Virmani R, Kolodgie FD, Farb A. Drug-eluting stents: are they really safe? Am
Heart Hosp J. 2004;2:85-8.
30. Virmani R, Farb A, Guagliumi G, Kolodgie FD. Drug-eluting stents: caution and
concerns for long-term outcome. Coron Artery Dis. 2004;15:313-8.
31. Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T, Mihalcsik L,
Tespili M, Valsecchi O, Kolodgie FD. Localized hypersensitivity and late
coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation. 2004;109:701-5.
|
|
Press Release